Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06756269 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

To Evaluate the Safety and Immunogenicity of 15-valent HPV Recombinant Vaccine in Chinese People Aged 9-45 Years

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Active, Not Recruiting to Recruiting
    • Primary completion date changed from estimate of Aug 13, 2025 to Oct 30, 2025
    • Site details revised
    v3
  2. Trial status: Not Yet Recruiting to Active, Not Recruiting
    • Start date changed from estimate of Jan 6, 2025 to Jan 15, 2025
    • Site contact updated
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety and Immunogenicity of 15-valent HPV vaccine in 9-45year-old participants.
Trial Details
NCT Number NCT06756269
Lead Sponsor Shanghai Bovax Biotechnology Co., Ltd.
Conditions
(from sponsor)		 HPV Infection, HPV-Related Carcinoma, HPV-Related Intraepithelial Neoplasia, Genital Wart
Related terms Condylomata Acuminata, Papillomavirus Infections
Enrollment 330 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov